RxDoctor Payments Data

Wilfredo Perez Vargas, MD

General Practice · Juana Diaz, PRNPI 1588653042

Payments from drug & device makers

$1,316in general payments, 2019–2025

Across 54 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$723
  • Boehringer Ingelheim$145
  • E.r. Squibb & Sons, L.L.C.$105
  • Sanofi-aventis U.S. LLC$98
  • PBG Puerto Rico LLC$63
  • Pfizer$40
  • plus $141 from 6 others

What the payments were for

  • Food & beverage$1,316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca28$723
Boehringer Ingelheim6$145
E.r. Squibb & Sons, L.L.C.5$105
Sanofi-aventis U.S. LLC4$98
PBG Puerto Rico LLC3$63
Pfizer2$40
Bayer Puerto Rico Inc.1$28
Bayer1$28
Dexcom, Inc.1$26
GSK1$21
AbbVie1$19
Merck1$19

How this compares

$1,316 in reported general payments places this provider in the 85th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$4,013
Medicare patients
22
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol106$108,353
EliquisApixaban58$62,526
JardianceEmpagliflozin33$42,848
JanumetSitagliptin Phos/Metformin Hcl23$27,924
SynthroidLevothyroxine Sodium277$22,571
OzempicSemaglutide21$20,728
XareltoRivaroxaban18$16,064
TrulicityDulaglutide13$14,717
Trijardy XrEmpaglifloz/Linaglip/Metformin19$14,306
Xigduo XrDapaglifloz Propaned/Metformin13$14,209
JentaduetoLinagliptin/Metformin Hcl16$12,956
JanuviaSitagliptin Phosphate12$9,714
Lagevrio (Eua)Molnupiravir12$9,507
MyrbetriqMirabegron15$8,840
LantusInsulin Glargine,hum.Rec.Anlog52$8,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$723$108,353106 claims
Boehringer IngelheimJardiance, Trijardy Xr, Jentadueto, Spiriva Respimat$145$76,39179 claims
PfizerEliquis$40$62,52658 claims
MerckJanumet, Januvia, Lagevrio (Eua)$19$47,14547 claims
AbbVieSynthroid$19$22,571277 claims
Sanofi-aventis U.S. LLCLantus$98$8,07152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Juana Diaz

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →